Click to download or view mobile version Author(s): Abstract or description: More Virtual Posters A US Patient Perspective on the Diagnosis and Burden of AxSpA Safety of a JAKi Across 15,000 Patient-Years of Data Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies ADD THE FIRST COMMENT If you are a health practitioner, you may Login/Register to comment.Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.